Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.

Published

Journal Article

The National Institute of Mental Health (NIMH)-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Project and related efforts have stimulated the initiation of several studies of pharmacologic treatments for cognitive impairment in schizophrenia. Cognitive remediation may provide an excellent platform for the provision of new learning opportunities and the acquisition of new skills for patients who are engaged in pharmacologic trials to improve cognition. However, it is not clear how a cognitive remediation intervention would be employed in multisite clinical trials. A meeting of experts on cognitive remediation and related methodological topics was convened to address the feasibility and study design issues for the development of a multisite trial of cognitive remediation in schizophrenia called the Cognitive Remediation in the Schizophrenia Trials Network study. This report details the findings from this meeting, which included the following 4 conclusions. (1) A multisite trial of a cognitive remediation intervention using a network of diverse research sites would be of great scientific value. (2) Various interventions could be employed for this multisite trial. (3) Programs that do not address key motivational and interpersonal aspects of cognitive remediation may benefit from supplementation with "bridging groups" that allows patients to meet with others and to apply their newly acquired cognitive skills to everyday life. (4) Before a multisite efficacy trial is initiated, a pilot study could demonstrate the feasibility of conducting a trial using a cognitive remediation intervention.

Full Text

Duke Authors

Cited Authors

  • Keefe, RSE; Vinogradov, S; Medalia, A; Silverstein, SM; Bell, MD; Dickinson, D; Ventura, J; Marder, SR; Stroup, TS

Published Date

  • September 2011

Published In

Volume / Issue

  • 37 / 5

Start / End Page

  • 1057 - 1065

PubMed ID

  • 20194249

Pubmed Central ID

  • 20194249

Electronic International Standard Serial Number (EISSN)

  • 1745-1701

International Standard Serial Number (ISSN)

  • 1787-9965

Digital Object Identifier (DOI)

  • 10.1093/schbul/sbq010

Language

  • eng